Defining immunological biomarkers for salivary gland carcinomas: First results from the prospective ImmoGlandula trial (NCT06047236)
Background: Salivary gland carcinomas (SGC) are a rare tumor entity that comes along with a high heterogeneity in terms of the histological features, the dignity or the outcome. Therefore, the therapeutic options for SGCs are limited. The inclusion of immunotherapy (IT) however, might improve the outcome [for full text, please go to the a.m. URL]
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-16
- DOI
- https://doi.org/10.3205/24hnosw04
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00